Guangzhou University of Traditional Chinese Medicine
With
Beijing Chest Hospital
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Sichuan Cancer Hospital and Research Institute
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Affiliated Hospital of Xinxiang Medical University, Henan province
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically or histologically confirmed non-small cell lung cancer (NSCLC)
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Presence of epidermal growth factor receptor (EGFR) mutation confirmed by genetic testing
Postoperative Cohort (must meet all of the above and the following):
Have undergone curative surgery for lung cancer with R0 resection
Are planned to receive or are currently receiving postoperative EGFR-TKI adjuvant therapy within 2 weeks
Advanced Cohort (must meet all of the above and the following):
Meet stage IIIB-IV criteria according to the 9th edition of the American Joint Committee on Cancer (AJCC), or have stage IIIB or below disease but have refused or are unable to tolerate surgical treatment
Have at least one measurable lesion
Are planned to receive or are currently receiving first-line EGFR-TKI therapy within 2 weeks
You may not be if
Unable to comply with baseline assessments
Pregnant or breastfeeding women
Presence of other uncontrolled malignancies
Presence of severe brain diseases or psychiatric disorders that affect the patient's ability to communicate or provide informed consent
Individuals without legal capacity, or those with medical or ethical reasons preventing continued participation in the study
Refusal to sign the informed consent form
Clareo Health | A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
